Biocryst Pharmaceuticals (BCRX) Free Cash Flow (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Free Cash Flow of -$62.4 million for Q1 2026, down 121.3% on a QoQ basis from $293.0 million in Q4 2025, and down 126.77% year-over-year from $233.1 million in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Free Cash Flow (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$62.4 million for Q1 2026.
- Quarterly Free Cash Flow fell 126.77% year-over-year to -$62.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $311.9 million (up 1317.42% YoY) and the FY2025 annual result came in at $346.8 million, up 766.59% from the prior year.
- Free Cash Flow was -$62.4 million for Q1 2026 at Biocryst Pharmaceuticals, down from $293.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $293.0 million in Q4 2025 and bottomed at -$78.2 million in Q1 2022.
- A 5-year average of -$1.5 million and a median of -$20.9 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2025 — Free Cash Flow soared 6250.67% — and 2026, when it slumped 126.77%.
- Biocryst Pharmaceuticals' Free Cash Flow stood at -$24.4 million in 2022, then jumped by 70.03% to -$7.3 million in 2023, then surged by 34.78% to -$4.8 million in 2024, then surged by 6250.67% to $293.0 million in 2025, then plunged by 121.3% to -$62.4 million in 2026.
- Business Quant data shows BCRX's Free Cash Flow at -$62.4 million in Q1 2026, $293.0 million in Q4 2025, and $41.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -62.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.40 Mn |
| Mar 31, 2026 | -62.40 Mn |
| Dec 31, 2025 | 293.02 Mn |
| Dec 31, 2025 | 293.02 Mn |
| Sep 30, 2025 | 41.03 Mn |
| Sep 30, 2025 | 41.03 Mn |
| Jun 30, 2025 | 40.23 Mn |
| Jun 30, 2025 | 40.23 Mn |
| Mar 31, 2025 | -27.52 Mn |
| Mar 31, 2025 | -27.52 Mn |
| Dec 31, 2024 | -4.76 Mn |
| Dec 31, 2024 | -4.76 Mn |
| Sep 30, 2024 | 7.80 Mn |
| Sep 30, 2024 | 7.80 Mn |
| Jun 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -1.13 Mn |
| Mar 31, 2024 | -53.92 Mn |
| Mar 31, 2024 | -53.92 Mn |
| Dec 31, 2023 | -7.30 Mn |
| Dec 31, 2023 | -7.30 Mn |